CMTDIC

YARS1 | 2006

Illustration of a DNA double helix overlaid on nerve cells, with text reading ‘Experts in CMT: CMT Genes and Subtypes Database

What Is CMTDIC?

CMTDIC is a type of CMT caused by mutations in the YARS1 gene. This gene provides instructions for making tyrosyl-tRNA synthetase (TyrRS), an enzyme that attaches the amino acid tyrosine to its cognate (corresponding) transfer RNA during protein synthesis. Mutations in the YARS1 gene are thought to cause nerve damage through a toxic gain-of-function mechanism, where the malfunctioning enzyme acquires harmful properties that progressively damage peripheral nerve axons.

CMTDIC is autosomal dominant, meaning that just one of the gene’s two copies needs a mutation to cause this subtype.

Clinical Features

CMTDID symptom onset is variable, ranging from early childhood to adulthood. Nerve conduction studies usually show conduction velocities and reduced amplitudes that fall between a demyelinating and an axonal form of CMT.

CMTDID symptoms may include:

  • Weakness in the feet and lower legs
  • Muscle atrophy
  • Foot drop
  • steppage-style walking pattern
  • Foot deformities, including high arches and hammertoes (clawed toes)
  • Reduced sensation
  • Muscle cramping
  • Reduced or absent reflexes
  • Enlarged peripheral nerves (hypertrophic nerves)
  • Clawing of the fingers
  • Additional symptoms not listed here

Disease Course

CMTDIC shows wide variability in severity and progression. Some individuals remain mildly affected, while others develop a more severe disease. Progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
CMTDIC

Classification
CMTDI

Inheritance Pattern
autosomal dominant

Genetic Context

HGNC-Approved Gene Symbol
YARS1

Gene Full Name
Tyrosyl-tRNA Synthetase 1

HGNC Gene Alias(es)
YTS, YARS, YRS, tyrRS

Chromosome
1p35.1

Zygosity of Responsible Variant
Heterozygous

Mitochondrial Involvement
No

ClinVar Pathogenic Variants

View CMTDIC ClinVar Variants

CMTDIC OMIM Entry

CMTDIC OMIM

YARS1 OMIM Entry

YARS1 OMIM

More Info

CMTDIC Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Disrupted Function and Axonal Distribution of Mutant Tyrosyl-tRNA Synthetase in Dominant Intermediate Charcot-Marie-Tooth Neuropathy

Authors

Jordanova, A., Irobi, J., Thomas, F. P., Van Dijck, P., Meerschaert, K., Dewil, M., Dierick, I., Jacobs, A., De Vriendt, E., Guergueltcheva, V., Rao, C. V., Tournev, I., Gondim, F. A., D’Hooghe, M., Van Gerwen, V., Callaerts, P., Van Den Bosch, L., Timmermans, J. P., Robberecht, W., Gettemans, J., Thevelein, J.M., De Jonghe, P., Kremensky, I., Timmerman, V.

Publication Date
January 22, 2006

Updated: May 9, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.


Illustrated cover graphic showing a split landform with branching directional arrows, two people with question marks above their heads, and the title ‘SORD Deficiency: Decoding This Newly Discovered and Confusing CMT Subtype.


CMT-SORD: What Is This Unique CMT Subtype?

CMT-SORD is a newly discovered CMT subtype driven by toxic sorbitol accumulation. This article explains how "SORD" works, why this subtype is different, and how it led to the fastest-moving therapeutic program in CMT history.